Conlight Medical Secures Nearly RMB 100 Million in Pre-B Funding to Strengthen Leadership in Psychiatric Pharmacogenomic Testing

Recently,CONLIGHT MEDICAL Laboratory Co., Ltd. (hereinafter referred to as “CONLIGHT MEDICAL”) announced the completion of its Pre-B financing round, raising nearly RMB 100 million.Led by Yuhong Capital. The funds from this financing round will be primarily used for the construction of the company’s GMP-compliant manufacturing facility, research and development and regulatory approval of new product pipelines, and market expansion. These efforts will accelerate CONLIGHT MEDICAL’s development in the field of precision medicine, particularly in pharmacogenetic testing for psychiatric disorders, both in breadth and depth.

Photo of the On-Site Investment Signing Ceremony Between CONLIGHT MEDICAL and Yuhong Capital (Provided by the Company)

Previously, CONLIGHT MEDICAL successively completed its angel, Series A, and Series A+ financing rounds between 2017 and 2020, with investors including Qiaojing Capital and other well-known healthcare investment funds, garnering increasing recognition from primary market investors for the company’s development.

Regarding this round of financing, He Jiong, Founder and CEO of CONLIGHT MEDICAL, stated, “The development of precision medicine follows its own inherent laws; it is a protracted endeavor that requires years of focused dedication and accumulation to achieve even modest breakthroughs in cognitive understanding and scientific research. Since 2017, the company has concentrated on the psychiatric sector, recognizing that this field had previously received insufficient attention. However, trends indicate that as living standards improve, mental health issues such as depression and anxiety are becoming increasingly prevalent, posing challenges that society must address. In response, the National Health Commission established the National Center for Mental Health as a directly affiliated institution in 2021, and various local governments have subsequently introduced ‘Ten-Year Plans for Mental Health.’ These developments are highly significant and timely for the industry. As a pioneer and leader in this field in China, our company is committed to serving this patient population by leveraging genetic technologies to provide high-quality solutions for precise medication management and long-term monitoring.”

Tang Ronghan, Founding Partner of Yuhong Capital, stated, “As a leader in precision medication for psychiatry in China, CONLIGHT MEDICAL has gathered numerous scientific research experts from both domestic and international arenas. It is the first medical institution in China to provide genetic testing services for psychiatric medication to clinical practice and boasts the largest sample size. The investment in CONLIGHT MEDICAL represents another significant practice of Yuhong Capital’s investment theme of ‘providing high-quality, inclusive healthcare to vulnerable groups,’ and it can effectively address certain shortcomings in China’s mental health sector.”

Zhang Hui, Vice President of CONLIGHT MEDICAL, stated, “Through years of dedicated efforts, the company has secured multiple national invention patents and several EU CE certificates. Leveraging platforms such as multiplex PCR and nucleic acid time-of-flight mass spectrometry, and utilizing AI technologies to analyze and learn from massive datasets in combination with clinical patient follow-up feedback, we have developed and continuously iterated algorithms tailored to the genetic characteristics of East Asian populations. The company is currently collaborating with Peking University Sixth Hospital on an ultra-large-scale prospective clinical trial involving 2,000 cases, aiming to facilitate the establishment of expert consensus and clinical guidelines. Subsequently, with the commissioning of our GMP-compliant manufacturing facility, the regulatory approval process for our in vitro diagnostic (IVD) products will be accelerated, paving the way for extensive expansion into overseas markets.”

Zhang Xuanrong, CFO of CONLIGHT MEDICAL, stated, “The company has taken note of the supportive policies for life sciences introduced by major stock exchanges. We will actively embrace this trend and, in accordance with capital market regulations and within a framework of standardized corporate governance, leverage a robust internal control system to continuously enhance compliance awareness across all staff and enrich various management tools. Our goal is to digitize business operations and enable data to speak for itself. In terms of collaboration with external intermediaries, we are gradually engaging top-tier professional teams. By maintaining proactive communication with regulators and systematically addressing common issues, we are solidifying our foundational work to prepare for future capital market pathways.”

Zhang Lei, Vice President of CONLIGHT MEDICAL, stated, “This successful financing round supports the company’s new strategy of ‘Digital Healthcare Services 2.0.’ The team will implement management upgrades to digitally transform multiple aspects, including user needs, behaviors, and service scenarios, with the aim of establishing the leading brand in precision psychiatry. In doing so, we remain committed to advancing our corporate mission of ‘Enhancing the Quality of Life.’”

Conlight Medical is a national high-tech enterprise centered on precision medicine, boasting a fully accredited third-party independent laboratory (compliant with the ISO 15189 quality management system standards) and a GMP-certified manufacturing facility. The company holds nearly 100 patents and intellectual property rights. Its core team members are predominantly alumni of the Chinese Academy of Sciences, Tsinghua University, Peking University, and other prestigious overseas universities, with prior professional experience at leading multinational corporations such as Pfizer, Bayer, and Lundbeck. Conlight Medical specializes in pharmacogenomics research and is dedicated to promoting its clinical translation and application. As the pioneer in psychiatric pharmacogenetic testing in China, it has established the largest database in this field. To date, the company has accumulated over 100,000 clinically significant drug-related genetic variants and clinical research data points, providing services to more than 1,000 medical institutions across China and serving over one million patient visits.

Shanghai Yuhong Capital (EHONG IMPACT CAPITAL), established in 2007, is an early practitioner of impact investment in China. It has received numerous accolades, including the “Investment Firm of the Year Award” from the China Social Enterprise and Impact Investment Forum and the “Impact Equity Investment Institution of the Year” award from Yicai (First Financial). Guided by the United Nations’ 17 Sustainable Development Goals, Yuhong is committed to supporting and investing in innovative enterprises dedicated to scaling solutions for social issues. In the healthcare sector, it has invested in companies such as Kangning Hospital, LvKang Medical and Elderly Care, and He’en Medical.